Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, GlaxoSmithKline Pharmaceuticals's enterprise value is ₹407,558 Mil.
GlaxoSmithKline Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹15,195 Mil. Therefore, GlaxoSmithKline Pharmaceuticals's EV-to-EBITDA for today is 26.82.
The historical rank and industry rank for GlaxoSmithKline Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
NSE:GLAXO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -292.35 Med: 36.59 Max: 488.37
Current: 26.82
During the past 13 years, the highest EV-to-EBITDA of GlaxoSmithKline Pharmaceuticals was 488.37. The lowest was -292.35. And the median was 36.59.
NSE:GLAXO's EV-to-EBITDA is ranked worse than 77.39% of 743
companies
in the Drug Manufacturers industry
Industry Median: 13.06
vs NSE:GLAXO: 26.82
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
GlaxoSmithKline Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
GlaxoSmithKline Pharmaceuticals's share price for today is ₹2569.70.
GlaxoSmithKline Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹63.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLAXO vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's EV-to-EBITDA falls into.
GlaxoSmithKline Pharmaceuticals's current Enterprise Value is ₹407,558 Mil.
GlaxoSmithKline Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹15,195 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a EV-to-EBITDA of 26.82 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on GlaxoSmithKline Pharmaceuticals. This is 27% below median its historical median of 36.59. According to the industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #575 out of 743 companies in the Drug Manufacturers industry, placing it in the top 77.4%.
Is GlaxoSmithKline Pharmaceuticals' EV-to-EBITDA too high?
GlaxoSmithKline Pharmaceuticals' current EV-to-EBITDA of 26.82 is 27% below median its 10-year median of 36.59. The Drug Manufacturers industry median EV-to-EBITDA is 13.06. GlaxoSmithKline Pharmaceuticals' value of 26.82 is 105.4% above this industry median. Based on the distribution chart, GlaxoSmithKline Pharmaceuticals ranks #575 out of 743 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #575 out of 743 companies for EV-to-EBITDA. This places GlaxoSmithKline Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.06. GlaxoSmithKline Pharmaceuticals' value of 26.82 is 105.4% above this benchmark. While the company's 10-year median is 36.59 vs. the industry median of 13.06, GlaxoSmithKline Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.06, based on 743 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pharmaceuticals's current EV-to-EBITDA of 26.82 is 105.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on GlaxoSmithKline Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current EV-to-EBITDA is 26.82, which is 27% below median its own 10-year median of 36.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,696.20, compared to a current price of ₹2,569.70 — trading 4.7% below its estimated fair value. The current EV-to-EBITDA is 26.82, which is 27% below median its 10-year median of 36.59 and 105.4% above the Drug Manufacturers industry median of 13.06. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current EV-to-EBITDA is 26.82 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹2,569.70 is trading 4.7% below its estimated GF Value™ of ₹2,696.20.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:GLAXO:
EV-to-EBITDA: 26.82 (27% below median its 10-year median of 36.59)
GF Value™: ₹2,696.20 vs. price of ₹2,569.70 (4.7% below fair value)
Industry Position: 105.4% above the Drug Manufacturers median (#575 of 743)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
77GF Score
Get the complete analysis for NSE:GLAXO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 
